Skip to main content

Table 2 Clinical-pathological characteristics of 913 primary PCa patients by curative intent treatment

From: The outcome of prostate cancer patients treated with curative intent strongly depends on survival after metastatic progression

First line therapy S/S + other
N (%)
RT/RT + HO
N (%)
P-value
Age (years)
  < 50 6 (1.6) 2 (0.4) < 0.001*
  ≥ 50 and <60 107 (28) 28 (5.3)
  ≥ 60 and <75 266 (69.6) 401 (75.5)
  ≥ 75 and <80 2 (0.5) 86 (16.2)
  ≥ 80 1 (0.3) 14 (2.6)
Stage
 T1-T2 191 (50.1) 360 (68.2) < 0.001*
 T3 186 (48.8) 156 (29.5)
 T4 4 (1.1) 12 (2.3)
Missing 1 3
Lymph nodes
 N0 322 (85.2) 514 (98.3) < 0.001*
 N1 56 (14.8) 9 (1.7)
Missing 4 8
PSA (ng/ml)
  < 10 189 (56.4) 180 (34.3) < 0.001*
 10–20 101 (30.2) 209 (39.9)
  ≥ 20 45 (13.4) 135 (25.8)
Missing 47 7
Gleason Score
 3–6 79 (22.1) 177 (35.9) < 0.001*
 7 192 (53.6) 171 (34.7)
 8–10 87 (24.3) 145 (29.4)
Missing 24 38
First metastatic event
 Bone-only 30 (40.54) 20 (32.26) 0.158
 Loco/LN-only 28 (37.4) 24 (38.71)
 Visceral-only 1 (1.35) 6 (9.68)
 Multiple site 15 (20.27) 12 (19.35)
Total (N) 382 531  
  1. S Surgery, RT Radiotherapy, HO Hormonal therapy; other: adjuvant therapy. *Significant value